3Sǒrenson S, Glimelius B, Nygren D. A. Systematic overview of chemotherapy effects in non - small cell lung cancer[J]. Acta Oncol ,2001,40(2/3) :327.
4Marugama R,Sagia K,Mitsudomi T,et al. Relationship between early recurrence and micrometastasis in thelymph nodes of patients with stage Ⅰ non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 1997,114(3) :535.
5Goldie JH. Scientific basis for adjuvant and primary(neoadjuvant) chemotherapy[J]. Semin Oncol, 1987,14(1) : 1.
6Holmes E C, Gail M. Surgical adjuvant therapy for stage Ⅱ and stage Ⅲ adenocarcinoma and large-cell undifferentiated Carcinoma[J] .J Clin Oncol, 1986,4(5) :710.
7Wada H, Miyahara R, Tanaka F, et al. Postoperative adjuvant chemotherapy with PVM and UFT in resected stage Ⅰ -- Ⅱ NSCLC: a randomized Clinical trial [J]. Eur J Cardiothoraco Surg, 1999,15(5) :438.
8Pisters K. Adjuvant and neoadjuvant therapy for early stage non-small cell lung cancer [ J ]. Semin Oncol, 2001,28(4)( 14suppl ) :23.
9Keller SM ,Adaks S,Wagner H,et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected Stage Ⅱ and ⅢA non-small cell lung cancer[J].N Engl J Med,2000,343(17) : 1217.
10PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small cell lung cancer:systematic review and meta-analysis of individual patient data from nine randomised controlled trials[J]. Lancet, 1998,352(2) : 257.
4De Leyn P, Vansteenkiste J, Deneffe G, et al. Result of induction chemotherapy followed by surgery in patients with stage Ⅲ A N2 NSCLC : importance of pre-treatment mediastinoscopy[ J]. Eur J Cardiothorac Surg, 1999,15 (5) :608 - 614.
5Calvert H. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents[ J]. Semin Oncol, 1999,26(2 Suppl 6) :3 - 10.
6Clarke SJ, Abratt R, Goedhals L, et al. Phase Ⅱ trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy patients with advanced non-small-cell lung cancer[ J ]. Ann Oncol, 2002,13 (5) :737 -741.
7Chambers AF, Matrisian LM. Changing views of the roleof matrix metalloproteinases in metastasis. J Natl Cancer Inst, 1997,89 (17) :1260-1270.
8Templeton NS, Stetler-Stevenson WG. Identification of a basal promoter for the human Mr 72,000 type Ⅳ collagenase gene and enhanced expression in a highly metastatic cell line. Cancer Res, 1991,51(22) : 6190-6193.
9Nawrocki B, Polette M, Marchand V, et al. Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int J Cancer,1997,72(4) : 556-564.
10Depierre A, Milleron B, Moro-sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage Ⅰ (except T1N0), Ⅱ and Ⅲ A non-small cell lung cancer. J ClinOncol,2002,20(1): 247-253.
